Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786607 | 0.83 | HTT (0.41) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL10103736 | 0.78 | GPR119 (0.34) | GPR119MAOAMAOB | |
| SCHEMBL10153364 | 0.78 | GPR119 (0.34) | GPR119MAOAMAOB | |
| SCHEMBL15114568 | 0.77 | GPR119 (0.36) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL669614 | 0.77 | GPR119 (0.36) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL25017499 | 0.77 | GPR119 (0.36) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL11202337 | 0.77 | GPR119 (0.36) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL1091056 | 0.77 | GPR119 (0.43) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL1090338 | 0.77 | GPR119 (0.36) | GPR119MAOAMAOBHTTIDH1 | |
| SCHEMBL9449631 | 0.77 | GPR119 (0.36) | GPR119MAOAMAOBHTTIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20190292173-A1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292173-A1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | GPR119, GPR3, GPR39 | GPR119 1/4885MAOA 2368/4885MAOB 1703/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | GPR119 10/4885MAOA 3157/4885MAOB 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.